ONCOLYTICS BIOTECH INC(ONCY)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ONCY Stock Analysis & AI Quality Score
AI stock analysis and institutional research for ONCOLYTICS BIOTECH INC (ONCY), a Healthcare sector company. ONCY is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), ONCOLYTICS BIOTECH INC reports net income of $-9.2M, free cash flow of $-7.3M. Top institutional holders of ONCY by reported 13-F value include Everhart Financial Group,, DOLIVER ADVISORS,, Cedar Mountain Advisors,, based on the most recent SEC filings. ONCY trades on the Nasdaq exchange and files with the SEC under CIK 1129928. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ONCY daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ONCOLYTICS BIOTECH INC directly from SEC EDGAR.
Net Income
Q1 2026
$-9.2M
Free Cash Flow
Q1 2026
$-7.3M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-26.2% YoYOperating Income
-12.5% YoYEPS (Diluted)
+0.0% YoYTotal Assets
-62.4% YoYOp. Cash Flow
-1.2% YoY| Metric | FY 2025 | FY 2024 |
|---|---|---|
| Net Income | $-28.8M -26.2% | $-22.8M |
| Operating Income | $-28.7M -12.5% | $-25.5M |
| EPS (Diluted) | $-0.30 +0.0% | $-0.30 |
| Total Assets | $7.6M -62.4% | $20.2M |
| Operating Cash Flow | $-20.1M -1.2% | $-19.9M |
AI Insight: ONCY Financial Trends
Insufficient financial data to assess trends; only Q1 2026 shows operating losses with negative equity.
• Q1 2026 net income and operating income both negative at $-9M; operating cash flow negative $-7M.
⚠ Equity deteriorated to $-5M in Q1 2026 from $-4M in Q4 2025; company now technically insolvent.
⚠ Revenue data absent across all periods; cannot assess commercial trajectory or growth rate.
AI Insight: ONCY Ratio Trends
Insufficient data: all ratio metrics are missing across the entire period.
• No financial ratio data available for any period from Q4 2019 through Q1 2026.
⚠ Unable to assess profitability, capital efficiency, or leverage trends without populated metrics.
Get alerted when ONCY's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ONCOLYTICS BIOTECH INC including:
Top Institutional Holders of ONCY
Everhart Financial Group, Inc.
$133.8K140,899 shDOLIVER ADVISORS, LP
$95.0K100,000 shCedar Mountain Advisors, LLC
$5.4K5,651 shDogwood Wealth Management LLC
$139.00146 shWOLFF WIESE MAGANA LLC
$30.0031 shPROFESSIONAL ADVISORY SERVICES INC
$19.0020,000 sh
| Fund | Value | Shares |
|---|---|---|
| Everhart Financial Group, Inc. | $133.8K | 140,899 |
| DOLIVER ADVISORS, LP | $95.0K | 100,000 |
| Cedar Mountain Advisors, LLC | $5.4K | 5,651 |
| Dogwood Wealth Management LLC | $139.00 | 146 |
| WOLFF WIESE MAGANA LLC | $30.00 | 31 |
| PROFESSIONAL ADVISORY SERVICES INC | $19.00 | 20,000 |
More Healthcare Companies
View all Healthcare →Put ONCY on your watchlist
Track score changes the day ONCOLYTICS BIOTECH INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ONCY a good stock to buy?
13F Pro's AI-powered analysis of ONCOLYTICS BIOTECH INC (ONCY) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ONCY are available on the ONCY stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ONCY?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ONCY. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ONCOLYTICS BIOTECH INC's investment landscape.